Abstract

[00121] The present invention relates to a label-free, high throughput method for determining an infectious virus titer in an aqueous sample comprising infectious virus, wherein the method comprises detecting the kinetics of morphological cell alteration, such as cell rounding, following viral infection, determining a parameter defining the curve of the morphological cell alteration as a function of time post infection and determining the infectious virus titer based on a standard curve of the infectious virus at a known infectious titer.

IPC Classes  ?

• C12N 7/00 - Viruses, e.g. bacteriophagesCompositions thereofPreparation or purification thereof
• C12Q 1/70 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving virus or bacteriophage

Abstract

This invention relates to binding molecules that bind specifically to CD137 and FAP and their use in medicine, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of cancer.

IPC Classes  ?

• C07K 16/40 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against enzymes
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61P 35/00 - Antineoplastic agents
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants

Abstract

The present invention relates to a method for identification of common patient-spanning tumor-specific T cell receptors (TCRs) and their corresponding antigens. The invention also relates to these TCR sequences, a nucleic acid encoding the TCR, and a T cell comprising the TCR and/or the encoding nucleic acid.

IPC Classes  ?

• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
• A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes
• A61K 40/11 - T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cellsLymphokine-activated killer [LAK] cells
• A61K 40/32 - T-cell receptors [TCR]
• C07K 14/725 - T-cell receptors
• C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA
• C12Q 1/6806 - Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
• C12Q 1/6809 - Methods for determination or identification of nucleic acids involving differential detection
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
• G16B 30/10 - Sequence alignmentHomology search

Goods & Services

Recorded computer software for sharing of data and information in the field of animal health Education services, namely, providing training programs and courses in the field of animal health Providing temporary use of on-line non-downloadable software and applications for sharing of data and information in the field of animal health

Goods & Services

Downloadable computer software and downloadable mobile applications for assisting patients with symptoms of central nervous system diseases and disorders; downloadable computer software and downloadable mobile applications to assist patients with mental illness and disorders. Therapeutic services for patients with symptoms of diseases and disorders of the central nervous system; therapeutic services for patients to support mental health.

Goods & Services

Organization and conducting of workshops, seminars and training courses for medical care, prevention, and healthcare management in the field of mental health disorders, including online and via the internet. Medical services in the field of mental health disorders; providing medical support in the monitoring of patients with mental health disorders; health counselling, individual medical counseling services provided to patients in the field of mental health disorders.

Abstract

177 are as herein defined.

IPC Classes  ?

• C07D 309/10 - Oxygen atoms
• C07C 41/48 - Preparation of compounds having groups
• C07C 43/13 - Saturated ethers containing hydroxy or O-metal groups
• C07C 43/313 - Compounds having groups containing halogen
• C07C 69/734 - Ethers
• C07C 303/28 - Preparation of esters or amides of sulfuric acidsPreparation of sulfonic acids or of their esters, halides, anhydrides or amides of esters of sulfonic acids by reaction of hydroxy compounds with sulfonic acids or derivatives thereof
• C07D 498/14 - Ortho-condensed systems

Goods & Services

Pharmaceutical preparations.

Goods & Services

Vaccines for poultry.

Goods & Services

Pharmaceutical preparations.

Abstract

The present invention relates to a process for the manufacture of a HER2 inhibitor and compounds that are useful as intermediates in this process.

IPC Classes  ?

• C07D 487/04 - Ortho-condensed systems

Goods & Services

Pharmaceutical preparations.

Goods & Services

Organization and conducting of workshops, seminars and training courses for medical care, prevention and healthcare management in the field of stroke diseases, including online and via the Internet. Medical services in the field of stroke diseases.

Abstract

The present invention relates to new [1,3]diazino[5,4-d]pyrimidines and derivatives of Formula (I) The present invention relates to new [1,3]diazino[5,4-d]pyrimidines and derivatives of Formula (I) The present invention relates to new [1,3]diazino[5,4-d]pyrimidines and derivatives of Formula (I) wherein the groups R1, R2, R3 and R4 have the meanings given in the claims and specification, their use as inhibitors of HER2 and its mutants, pharmaceutical compositions which contain such compounds and their use as medicaments, especially as agents for treatment and/or prevention of oncological diseases.

IPC Classes  ?

• C07D 487/04 - Ortho-condensed systems
• A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
• A61K 47/32 - Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers
• A61K 47/36 - PolysaccharidesDerivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
• C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or

Abstract

A viral inactivation device including at least one experimental continuous viral inactivation reactor having at least an inlet, an outlet, and a tubular flow path and a computer system that, based on the experimental continuous viral inactivation reactor can design, select, make, and/or manufacture a scaled actual reactor. The tubular flow path includes a set of alternating turns that form a serpentine or an interwoven pattern between the inlet and the outlet.

IPC Classes  ?

• C12M 1/36 - Apparatus for enzymology or microbiology including condition or time responsive control, e.g. automatically controlled fermentors
• C12M 1/00 - Apparatus for enzymology or microbiology
• C12M 1/34 - Measuring or testing with condition measuring or sensing means, e.g. colony counters

Abstract

The present invention generally relates to the field of recombinant gene expression in host cells. In particular, the invention relates to a recombinant human myeloid-derived growth factor (MYDGF) protein that exhibits a minimal degree of degradation upon expression in a host cell. The recombinant protein is therefore highly suitable for medical use, in particular for treating heart tissue damage and preventing cell death in myocardial tissue. The invention also provides a nucleic acid which encodes the recombinant protein and a host cell that expresses the recombinant protein. The invention also provides a method for producing the recombinant protein in a host cell.

IPC Classes  ?

• C07K 14/475 - Growth factorsGrowth regulators
• A61K 38/18 - Growth factorsGrowth regulators

Abstract

The present disclosure relates to the treatment of cancer by using an anti-SIRPα (Signal regulatory protein alpha) antibody or antigen-binding fragment thereof. In particular, the present disclosure relates to a method of using and uses of an anti-SIRPα antibody or antigen-binding fragment thereof to treat cancer including, in a treatment regimen that optionally includes the administration of an additional therapeutic agent.

IPC Classes  ?

• A61P 35/00 - Antineoplastic agents
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants

Abstract

The present disclosure relates to the treatment of a SIRPα (signal regulatory protein alpha) pathway disease or disorder, such as a liver disease or disorder, by administering an anti-SIRPα antibody or antigen-binding fragment thereof to a subject in need thereof.

IPC Classes  ?

• A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants

Goods & Services

Downloadable computer software and downloadable mobile applications for assisting patients with symptoms of central nervous system diseases and disorders; downloadable computer software and downloadable mobile applications to assist patients with mental illness and disorders. Therapeutic services for patients with symptoms of diseases and disorders of the central nervous system; therapeutic services for patients to support mental health.

Abstract

This invention relates to compounds of Formula (I) useful as synthons for a general synthetic method for making chiral phosphorothioates, to their preparation and to their use in a robust large scale process for making P-chiral phosphorothioates. This invention relates to compounds of Formula (I) useful as synthons for a general synthetic method for making chiral phosphorothioates, to their preparation and to their use in a robust large scale process for making P-chiral phosphorothioates.

IPC Classes  ?

• C07F 9/58 - Pyridine rings
• C07H 1/02 - Phosphorylation
• C07H 19/10 - Pyrimidine radicals with the saccharide radical being esterified by phosphoric or polyphosphoric acids
• C07H 19/20 - Purine radicals with the saccharide radical being esterified by phosphoric or polyphosphoric acids
• C07H 21/04 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical

Goods & Services

Downloadable computer software and downloadable mobile applications for assisting patients with symptoms of central nervous system diseases and disorders; downloadable computer software and downloadable mobile applications to assist patients with mental illness and disorders. Therapeutic services for patients with symptoms of diseases and disorders of the central nervous system; therapeutic services for patients to support mental health.

Goods & Services

Scientific research in the field of prevention and treatment of cardiovascular diseases; providing medical and scientific research information in the field of cardiovascular diseases.

Abstract

A resin composite 10 according to the present invention includes: a coating powder 20 used in an electrostatic coating method or a fluidized immersion coating method; an inorganic alkali 30; and a thermoplastic resin 40. The coating powder 20 includes a thermal film-forming resin 26 and a crosslinking agent, and can be molded by one of the following molding methods: injection molding, blow molding, extrusion molding, and vacuum molding.

IPC Classes  ?

• C08L 101/00 - Compositions of unspecified macromolecular compounds
• C08J 3/205 - Compounding polymers with additives, e.g. colouring in the presence of a liquid phase
• C08J 5/00 - Manufacture of articles or shaped materials containing macromolecular substances
• C08K 3/22 - OxidesHydroxides of metals
• C08K 3/26 - CarbonatesBicarbonates
• C08L 67/00 - Compositions of polyesters obtained by reactions forming a carboxylic ester link in the main chainCompositions of derivatives of such polymers
• C09D 5/03 - Powdery paints
• C09D 7/61 - Additives non-macromolecular inorganic
• C09D 201/00 - Coating compositions based on unspecified macromolecular compounds

Goods & Services

Scientific research in the field of prevention and treatment of cardiovascular diseases; providing medical and scientific research information in the field of cardiovascular diseases.

Abstract

The present invention relates to a method for structure elucidation of the structure of an unknown chemical compound from a measured spectrum of a sample. The method includes at least one machine learning model, in particular a first machine learning model that generates structures of chemical compounds and/or a second machine learning model that generates predicted spectra from the structures.

IPC Classes  ?

• G16C 20/20 - Identification of molecular entities, parts thereof or of chemical compositions
• G06N 3/042 - Knowledge-based neural networksLogical representations of neural networks
• G06N 3/045 - Combinations of networks
• G06N 3/0464 - Convolutional networks [CNN, ConvNet]
• G06N 3/0475 - Generative networks
• G06N 3/094 - Adversarial learning
• G16C 20/70 - Machine learning, data mining or chemometrics

Goods & Services

Scientific research in the field of prevention and treatment of metabolic and cardiovascular diseases; providing medical and scientific research information in the field of metabolic and cardiovascular diseases..

Abstract

The present disclosure provides cis-5-(hydroxymethyl)morpholine-2-carboxamides that are agonists of somatostatin receptor 4 (SSTR4), and are therefore useful for the treatment of diseases or medical conditions associated with SSTR4. Also provided are pharmaceutical compositions containing the same, and processes for preparing said compounds. The present disclosure provides cis-5-(hydroxymethyl)morpholine-2-carboxamides that are agonists of somatostatin receptor 4 (SSTR4), and are therefore useful for the treatment of diseases or medical conditions associated with SSTR4. Also provided are pharmaceutical compositions containing the same, and processes for preparing said compounds.

IPC Classes  ?

• C07D 265/30 - 1,4-OxazinesHydrogenated 1,4-oxazines not condensed with other rings
• A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• C07D 413/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

The present invention relates to processes for preparing glucopyranosyl-substituted benzyl-benzene derivatives of general formula III, The present invention relates to processes for preparing glucopyranosyl-substituted benzyl-benzene derivatives of general formula III, The present invention relates to processes for preparing glucopyranosyl-substituted benzyl-benzene derivatives of general formula III, wherein R1, R2 and R′ are defined according to claim 1; and the use of such processes in the synthesis of SGLT2 inhibitors.

IPC Classes  ?

• C07H 1/00 - Processes for the preparation of sugar derivatives
• C07H 7/00 - Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond

Abstract

Methods of protein production in a linked culture and production bioreactor system are provided. Such methods include a culture bioreactor (N-1 bioreactor) linked to production bioreactor (N bioreactor). More specifically, the methods include (a) culturing cells with a gene that encodes the protein of interest in a continuous perfusion culture bioreactor (N-1 bioreactor); inoculating a continuously stirred tank reactor (CSTR) production bioreactor (N bioreactor) with cells obtained from step (a); and culturing the cells in the CSTR production bioreactor under conditions that allow production of the protein of interest.

IPC Classes  ?

• C12M 1/00 - Apparatus for enzymology or microbiology
• C07K 16/00 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies
• C12M 1/06 - Apparatus for enzymology or microbiology with gas introduction means with agitator, e.g. impeller
• C12N 5/00 - Undifferentiated human, animal or plant cells, e.g. cell linesTissuesCultivation or maintenance thereofCulture media therefor
• C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues
• C12P 21/02 - Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione

Abstract

The present invention relates to anti-IL-23p19 binding compounds, in particular new humanized anti-IL-23p19 antibodies and therapeutic and diagnostic methods and compositions for using the same.

IPC Classes  ?

• C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides

Abstract

The present disclosure provides certain tetrazole derivatives that are inhibitors of transient receptor potential ankyrin 1 (TRPA1), and are therefore useful for the treatment of diseases treatable by inhibition of TRPA1. Also provided are pharmaceutical compositions containing the same, and processes for preparing said compounds.

IPC Classes  ?

• C07D 403/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
• C07D 403/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
• C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
• C07D 409/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
• C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Abstract

Methods of treating or preventing alcoholic liver disease are disclosed, the methods comprising administering to a subject a therapeutically or prophylactically effective amount of an agent capable of inhibiting interleukin 11 (IL-11)-mediated signalling.

IPC Classes  ?

• C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
• A61K 38/20 - Interleukins
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides

Goods & Services

Downloadable computer software and downloadable mobile applications for assisting patients with symptoms of central nervous system diseases and disorders; downloadable computer software and downloadable mobile applications to assist patients with mental illness and disorders. Therapeutic services for patients with symptoms of diseases and disorders of the central nervous system; therapeutic services for patients to support mental health.

Goods & Services

Downloadable computer software and downloadable mobile applications for assisting patients with symptoms of central nervous system diseases and disorders; downloadable computer software and downloadable mobile applications to assist patients with mental illness and disorders. Therapeutic services for patients with symptoms of diseases and disorders of the central nervous system; therapeutic services for patients to support mental health.

Abstract

The present invention relates to the finding that certain DPP-4 inhibitors are particularly suitable for treating and/or preventing metabolic diseases, particularly diabetes, in patients with insufficient glycemic control despite a therapy with an oral and/or a non-oral antidiabetic drug.

IPC Classes  ?

• A61K 31/522 - Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 31/155 - Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (HN=C(OH)NH2), isothiourea (HN=C(SH)—NH2)
• A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
• A61K 31/64 - Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
• A61K 38/28 - Insulins
• A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Abstract

The present invention relates to a HER2 inhibitor useful in the prevention and/or treatment of cancer, in particular, to methods of treatment or uses comprising avoiding, contraindicating, reducing or discontinuing concomitant use or co-administration of a CYP3A and/or P-gp modulator. The present invention also relates to a HER2 inhibitor useful in the prevention and/or treatment of cancer, in particular, to methods of treatment or uses comprising concomitant use, co-administration or combination of a CYP3A and/or P-gp modulator.

IPC Classes  ?

• A61K 31/4995 - Pyrazines or piperazines forming part of bridged ring systems
• A61K 31/03 - Halogenated hydrocarbons carbocyclic aromatic
• A61K 31/4468 - Non-condensed piperidines, e.g. piperocaine having a nitrogen atom directly attached in position 4, e.g. clebopride, fentanyl
• A61K 31/573 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
• A61P 35/00 - Antineoplastic agents

Goods & Services

Scientific research in the field of prevention and treatment of metabolic and cardiovascular diseases; providing medical and scientific research information in the field of metabolic and cardiovascular diseases..

Goods & Services

Scientific research in the field of prevention and treatment of cardiovascular diseases; providing medical and scientific research information in the field of cardiovascular diseases..

Abstract

The present invention provides recombinant herpes virus of turkeys (HVT) viral vectors comprising a heterologous polynucleotide encoding an avian influenza antigen. The recombinant viral vectors are suitable for use in immunogenic compositions and vaccines, and can provide protection against avian influenza and other pathogens when administered to an avian.

IPC Classes  ?

• A61K 39/12 - Viral antigens
• A61P 31/14 - Antivirals for RNA viruses
• A61P 31/16 - Antivirals for RNA viruses for influenza or rhinoviruses
• A61P 31/20 - Antivirals for DNA viruses
• C12N 7/00 - Viruses, e.g. bacteriophagesCompositions thereofPreparation or purification thereof

Abstract

The present invention relates to the protein myeloid-derived growth factor (MYDGF) or nucleic acids encoding said protein for use in treating or preventing a liver disorder. The present invention also relates to vectors comprising the nucleic acid, host cells expressing the nucleic acid, and methods for use in treating a liver disorder.

IPC Classes  ?

• A61K 38/18 - Growth factorsGrowth regulators
• A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• A61K 31/70 - CarbohydratesSugarsDerivatives thereof
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy

Abstract

The present invention relates to methods for preventing or treating acute or chronic heart failure and for reducing the risk of cardiovascular death, hospitalization for heart failure and other conditions in patients with preserved or reduced ejection fraction by administering empagliflozin to the patient.

IPC Classes  ?

• A61K 31/351 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
• A61K 9/20 - Pills, lozenges or tablets
• A61K 31/7048 - Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Abstract

The present invention provides recombinant Newcastle disease virus (NDV) viral vectors comprising a heterologous polynucleotide encoding an avian influenza antigen. The recombinant viral vectors are suitable for use in immunogenic compositions and vaccines, and can provide protection against avian influenza and other pathogens when administered to an avian.

IPC Classes  ?

• A61K 39/12 - Viral antigens
• A61P 31/14 - Antivirals for RNA viruses
• A61P 31/16 - Antivirals for RNA viruses for influenza or rhinoviruses

Abstract

The present invention provides recombinant canine distemper virus (CDV) viral vectors comprising a heterologous polynucleotide encoding an avian influenza antigen. The recombinant viral vectors are suitable for use in immunogenic compositions and vaccines, and can provide protection against avian influenza and other pathogens when administered to an animal.

IPC Classes  ?

• A61K 39/12 - Viral antigens
• A61P 31/14 - Antivirals for RNA viruses
• A61P 31/16 - Antivirals for RNA viruses for influenza or rhinoviruses
• C07K 14/005 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from viruses

Goods & Services

Organization and conducting of workshops, seminars and training courses for medical care, prevention and healthcare management in the field of stroke diseases, including online and via the Internet. Medical services in the field of stroke diseases.

Goods & Services

(1) Organization and conducting of workshops, seminars and training courses for medical care, prevention and healthcare management in the field of stroke diseases, including online and via the Internet. (2) Medical services in the field of stroke diseases.

Goods & Services

Downloadable computer software and downloadable mobile applications for assisting patients with symptoms of central nervous system diseases and disorders; downloadable computer software and downloadable mobile applications to assist patients with mental illness and disorders. Therapeutic services for patients with symptoms of diseases and disorders of the central nervous system; therapeutic services for patients to support mental health.

Goods & Services

Downloadable computer software and downloadable mobile applications for assisting patients with symptoms of central nervous system diseases and disorders; downloadable computer software and downloadable mobile applications to assist patients with mental illness and disorders. Therapeutic services for patients with symptoms of diseases and disorders of the central nervous system; therapeutic services for patients to support mental health.

Abstract

The present invention relates i.a. to an IBV (infectious bronchitis virus) encoding for a heterologous DMV S (spike) protein or fragment thereof. Further, the present invention relates to an immunogenic composition comprising said IBV encoding for a heterologous DMV S (spike) protein or fragment thereof. Furthermore, the present invention relates to methods for immunizing a subject comprising administering to such subject the immunogenic composition of the present invention. Moreover, the present invention relates to methods of treating or preventing clinical signs caused by IBV in a subject of need, the method comprising administering to the subject a therapeutically effective amount of an immunogenic composition according to the present invention.

IPC Classes  ?

• A61K 39/215 - Coronaviridae, e.g. avian infectious bronchitis virus
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61P 31/14 - Antivirals for RNA viruses
• C07K 14/005 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from viruses
• C12N 7/00 - Viruses, e.g. bacteriophagesCompositions thereofPreparation or purification thereof

Abstract

The invention relates to a method for purifying and enriching a target product selected from immunoglobulins or other proteins; or plasmid DNA, genomic DNA, RNA or other nucleic acids or viruses, wherein the measured electrical conductivity values and/or the measured turbidity values of the phases are used for adjusting the position of the phases in a separating device (10, 100) and for separating the phases. The invention also relates to a device for carrying out the method and to the use thereof.

IPC Classes  ?

• B01D 17/04 - Breaking emulsions
• B01D 11/04 - Solvent extraction of solutions which are liquid
• B01D 17/12 - Auxiliary equipment particularly adapted for use with liquid-separating apparatus, e.g. control circuits
• C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA
• G01N 27/02 - Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating impedance

Abstract

The present invention relates to pharmaceutical compositions of DPP IV inhibitors with an amino group, their preparation and their use to treat diabetes mellitus.

IPC Classes  ?

• A61K 31/522 - Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 9/20 - Pills, lozenges or tablets
• A61K 9/28 - DrageesCoated pills or tablets
• A61K 31/517 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine

Abstract

The specification describes the use of selected DPP IV inhibitors for the treatment of physiological functional disorders and for reducing the risk of the occurrence of such functional disorders in at-risk patient groups. In addition, the use of the above-mentioned DPP IV inhibitors in conjunction with other active substances is described, by means of which improved treatment outcomes can be achieved. These applications may be used to prepare corresponding medicaments.

IPC Classes  ?

• A61K 31/522 - Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
• A61K 31/155 - Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (HN=C(OH)NH2), isothiourea (HN=C(SH)—NH2)
• A61K 31/197 - Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
• A61K 31/4184 - 1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
• A61K 31/4985 - Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
• A61K 31/5025 - PyridazinesHydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
• A61K 31/52 - Purines, e.g. adenine
• A61K 31/7048 - Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Goods & Services

Scientific research in the field of prevention and treatment of cardiovascular diseases; providing medical and scientific research information in the field of cardiovascular diseases.

Abstract

A method, being executed by a computer or signal processor or system or apparatus, for processing a first video data set comprising first video data of a first video depicting a plurality of moving objects. The method comprises generating one or more further video data sets from the first video data set, such that each further video data set of the one or more further video data sets comprises further video data of a further video, such that exactly one moving object of the plurality of moving objects is associated with said further video data set.

IPC Classes  ?

• G06T 7/20 - Analysis of motion

Abstract

The present disclosure provides certain piperidinylpyridinylcarbonitrile derivatives, and pharmaceutically acceptable salts thereof, that are inhibitors of Glutaminyl-peptide cyclotransferase (QPCT) and glutaminyl-peptide cyclotransferase-like protein (QPCTL), and are therefore useful for the treatment of diseases treatable by inhibition of QPCT/L. Also provided are pharmaceutical compositions containing the same, and processes for preparing said compounds.

IPC Classes  ?

• C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
• A61K 31/4545 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
• A61K 31/501 - PyridazinesHydrogenated pyridazines not condensed and containing further heterocyclic rings
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• C07D 471/04 - Ortho-condensed systems

Abstract

Disclosed are methods for treating focal segmental glomerulosclerosis (FSGS), comprising administering to a patient in need thereof a pharmaceutically effective amount of a compound of formula (I), wherein R1 to R7, A, L and Y are as defined herein. Also disclosed are pharmaceutical compositions comprising the compound of formula (I) and their use for treating FSGS.

IPC Classes  ?

• A61K 31/501 - PyridazinesHydrogenated pyridazines not condensed and containing further heterocyclic rings
• A61P 13/12 - Drugs for disorders of the urinary system of the kidneys

Abstract

The present disclosure provides certain piperidinylpyridinylcarbonitrile derivatives, and pharmaceutically acceptable salts thereof, that are inhibitors of Glutaminyl-peptide cyclotransferase (QPCT) and glutaminyl-peptide cyclotransferase-like protein (QPCTL), and are therefore useful for the treatment of diseases treatable by inhibition of QPCT/L. Also provided are pharmaceutical compositions containing the same, and processes for preparing said compounds.

IPC Classes  ?

• C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
• A61K 31/4545 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
• A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• C07D 471/04 - Ortho-condensed systems
• C07D 487/04 - Ortho-condensed systems

Abstract

The present disclosure provides certain piperidinylpyridinylcarbonitrile derivatives, and pharmaceutically acceptable salts thereof, that are inhibitors of Glutaminyl-peptide cyclotransferase (QPCT) and glutaminyl-peptide cyclotransferase-like protein (QPCTL), and are therefore useful for the treatment of diseases treatable by inhibition of QPCT/L. Also provided are pharmaceutical compositions containing the same, and processes for preparing said compounds.

IPC Classes  ?

• C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
• C07D 471/04 - Ortho-condensed systems
• A61K 31/444 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
• A61P 35/00 - Antineoplastic agents

Abstract

The present invention relates to methods for using soluble guanylate cyclase (sGC) activators for preventing, slowing the progression of, delaying or treating clinically significant portal hypertension (CSPH) and decompensated cirrhosis due to non-cholestatic liver disease.

IPC Classes  ?

• A61K 31/4155 - 1,2-Diazoles not condensed and containing further heterocyclic rings
• A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
• A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• A61P 9/12 - Antihypertensives

Abstract

The present invention relates to the field of oncolytic viruses and in particular to a recombinant rhabdovirus, such as vesicular stomatitis virus encoding in its genome for a CD80 extracellular domain Fc-fusion protein. The invention is further directed to the use of the recombinant virus in the treatment of cancer, and also to methods for producing such viruses.

IPC Classes  ?

• A61K 35/766 - Rhabdovirus, e.g. vesicular stomatitis virus
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• C07K 14/705 - ReceptorsCell surface antigensCell surface determinants

Abstract

Methods of protein production in continuous perfusion mammalian cell culture bioreactors are provided. Methods for continuous perfusion culture by allowing cells to self-regulate the rate of addition of perfusion medium to the bioreactor via a pH change are presented. Compositions comprising the perfusion medium as well as the process advantages of using hi-end pH control of perfusion or HIPCOP are also presented.

IPC Classes  ?

• C12M 1/00 - Apparatus for enzymology or microbiology
• C12M 1/34 - Measuring or testing with condition measuring or sensing means, e.g. colony counters
• C12N 5/00 - Undifferentiated human, animal or plant cells, e.g. cell linesTissuesCultivation or maintenance thereofCulture media therefor

Abstract

The present disclosure provides certain piperidinylpyridinylcarbonitrile derivatives, and pharmaceutically acceptable salts thereof, that are inhibitors of Glutaminyl-peptide cyclotransferase (QPCT) and glutaminyl-peptide cyclotransferase-like protein (QPCTL), and are therefore useful for the treatment of diseases treatable by inhibition of QPCT/L. Also provided are pharmaceutical compositions containing the same, and processes for preparing said compounds.

IPC Classes  ?

• C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
• A61K 31/4545 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
• A61K 31/5025 - PyridazinesHydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
• A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
• A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
• C07D 471/04 - Ortho-condensed systems
• C07D 487/04 - Ortho-condensed systems
• C07D 491/048 - Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
• C07D 498/04 - Ortho-condensed systems

Abstract

Disclosed are methods for treating focal segmental glomerulosclerosis (FSGS), comprising administering to a patient in need thereof a pharmaceutically effective amount of a compound of formula (I), Disclosed are methods for treating focal segmental glomerulosclerosis (FSGS), comprising administering to a patient in need thereof a pharmaceutically effective amount of a compound of formula (I), Disclosed are methods for treating focal segmental glomerulosclerosis (FSGS), comprising administering to a patient in need thereof a pharmaceutically effective amount of a compound of formula (I), wherein R1 to R7, A, L and Y are as defined herein. Also disclosed are pharmaceutical compositions comprising the compound of formula (I) and their use for treating FSGS.

IPC Classes  ?

• A61K 31/4545 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
• A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
• A61K 31/499 - Spiro-condensed pyrazines or piperazines
• A61K 31/4995 - Pyrazines or piperazines forming part of bridged ring systems
• A61K 31/501 - PyridazinesHydrogenated pyridazines not condensed and containing further heterocyclic rings
• A61K 31/5386 - 1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems

Abstract

This invention relates to binding molecules that bind specifically Vascular Endothelial Growth Factor (VEGF) and Tropomyosin receptor kinase B (TrkB) and their use in medicine, pharmaceutical compositions comprising the same, and methods of using the same as agents for treatment and/or prevention of diseases of the eye.

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61P 27/02 - Ophthalmic agents
• C07K 16/22 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors

Abstract

The present invention relates to treatment of chronic kidney disease by administering to patients in need thereof a compound of formula (I): The present invention relates to treatment of chronic kidney disease by administering to patients in need thereof a compound of formula (I): The present invention relates to treatment of chronic kidney disease by administering to patients in need thereof a compound of formula (I): and pharmaceutically acceptable salts thereof, wherein Cy, R1 and R2 are as defined herein. The invention further relates to the use of the compounds of formula (I) in combination with sodium-glucose cotransporter-2 (SGLT2) inhibitors.

IPC Classes  ?

• A61K 31/4188 - 1,3-Diazoles condensed with heterocyclic ring systems, e.g. biotin, sorbinil
• A61K 31/4709 - Non-condensed quinolines containing further heterocyclic rings
• A61P 13/12 - Drugs for disorders of the urinary system of the kidneys

Abstract

The present invention encompasses compounds of formula (I), wherein the groups A, R1, R3 and R4 have the meanings given in the claims and specification, proteolysis targeting chimera (PROTACs) comprising such compounds of formula (I), their use as degraders of SMARCA, pharmaceutical compositions which contain PROTACs of this kind and their medical uses, especially as agents for treatment and/or prevention of oncological diseases. The present invention encompasses compounds of formula (I), wherein the groups A, R1, R3 and R4 have the meanings given in the claims and specification, proteolysis targeting chimera (PROTACs) comprising such compounds of formula (I), their use as degraders of SMARCA, pharmaceutical compositions which contain PROTACs of this kind and their medical uses, especially as agents for treatment and/or prevention of oncological diseases.

IPC Classes  ?

• A61K 47/55 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
• C07D 487/04 - Ortho-condensed systems
• C07D 487/14 - Ortho-condensed systems
• C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or

Abstract

The invention provides a method of suppressing gene expression, comprising providing a mammalian cell with a suppression target RNA molecule comprising a heterologous RNAi target site operatively linked to a RNA sequence from a gene of interest, or with a DNA encoding said suppression target RNA molecule; providing to the cell an inhibitory RNA that has a complementary nucleotide sequence to the heterologous RNAi target site; wherein binding of the inhibitory RNA to the heterologous RNAi target site suppresses gene expression of the operatively linked RNA sequence from the gene of interest; and wherein said heterologous RNAi target site has a size of at least 18 nucleotides in length. The invention further provides nucleic acids and cells suitable for such a method.

IPC Classes  ?

• C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides

Abstract

The present disclosure provides certain piperidinylpyridinylcarbonitrile derivatives, and pharmaceutically acceptable salts thereof, that are inhibitors of Glutaminyl-peptide cyclotransferase (QPCT) and glutaminyl-peptide cyclotransferase-like protein (QPCTL), and are therefore useful for the treatment of diseases treatable by inhibition of QPCT/L. Also provided are pharmaceutical compositions containing the same, and processes for preparing said compounds.

IPC Classes  ?

• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• A61P 35/00 - Antineoplastic agents
• C07D 471/04 - Ortho-condensed systems
• C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
• C07D 487/04 - Ortho-condensed systems
• A61K 31/4545 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
• A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings

Abstract

The present disclosure provides certain piperidinyIpyridinylcarbonitrile derivatives, and pharmaceutically acceptable salts thereof, that are inhibitors of Glutaminyl-peptide cyclotransferase (QPCT) and glutaminyl-peptide cyclotransferase-like protein (QPCTL), and are therefore useful for the treatment of diseases treatable by inhibition of QPCT/L. Also provided are pharmaceutical compositions containing the same, and processes for preparing said compounds.

IPC Classes  ?

• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• A61P 35/00 - Antineoplastic agents
• C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
• C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
• C07D 471/04 - Ortho-condensed systems
• C07D 487/04 - Ortho-condensed systems
• C07D 491/048 - Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
• C07D 498/04 - Ortho-condensed systems
• A61K 31/4545 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
• A61K 31/5025 - PyridazinesHydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
• A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings

Goods & Services

(1) Scientific research in the field of prevention and treatment of cardiovascular diseases; providing medical and scientific research information in the field of cardiovascular diseases.

Goods & Services

(1) Pharmaceutical preparations for the prevention and treatment of diseases and disorders of the alimentary tract and metabolism, namely, renal diseases, liver diseases, pancreas diseases, digestive system disorders, gastrointestinal diseases and disorders, obesity; pharmaceutical preparations for the prevention and treatment of diseases and disorders of the blood and blood forming organs, namely, vascular diseases, hematology, blood disorders; pharmaceutical preparations for the prevention and treatment of cardiovascular diseases and disorders, musculoskeletal diseases and disorders, central nervous system diseases and disorders, peripheral nervous system diseases and disorders; pharmaceutical preparations for the prevention and treatment of genitourinary diseases, urological diseases, infertility, sexually transmitted diseases, inflammatory pelvic diseases; pharmaceutical preparations for the prevention and treatment of respiratory diseases; pharmaceutical preparations for the prevention and treatment of dermatological diseases and disorders, damaged skin and tissues, namely, rashes, sores, psoriasis, eczema; pharmaceutical preparations for the prevention and treatment of inflammation and inflammatory diseases and disorders, namely, anti-inflammatories; pharmaceutical preparations for the prevention and treatment of ophthalmological diseases and disorders; pharmaceutical preparations for the treatment and prevention of hormonal diseases and disorders; pharmaceutical preparations for the treatment and prevention of infectious diseases and disorders and viral infections, namely, antibiotics, anti-infectives, antivirals; pharmaceutical preparations for the prevention and treatment of oncological diseases; pharmaceutical preparations for the prevention and treatment of auto-immune diseases and disorders; pharmaceutical preparations, namely, cell based immune therapeutics for treatment of cancer; pharmaceutical preparations, namely, cell based immune therapeutics for treatment of immunological diseases, namely, autoimmune diseases and disorders; pharmaceutical preparations, namely, cell based immune therapeutics for treatment of infectious diseases, namely viral infections.

Goods & Services

Scientific research in the field of prevention and treatment of cardiovascular diseases; providing medical and scientific research information in the field of cardiovascular diseases.

Goods & Services

Scientific research in the field of prevention and treatment of cardiovascular diseases; providing medical and scientific research information in the field of cardiovascular diseases.

Abstract

The subject technology relates to a cell retention device and method for use in a perfusion cell culture system where the cell retention device includes a hollow-fiber filter having an average pore size ranging from about 0.5 to about 20 μm and having the ability to operate under perfusion cell culture conditions for up to 35 days without being clogged or losing its product sieving ability by more than 20%.

IPC Classes  ?

• C12M 1/00 - Apparatus for enzymology or microbiology

Abstract

The present invention relates to compounds of formula (I): The present invention relates to compounds of formula (I): The present invention relates to compounds of formula (I): or pharmaceutically acceptable salts thereof, wherein R1, R2, X, Y, and HET are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

IPC Classes  ?

• C07D 471/04 - Ortho-condensed systems
• C07D 231/12 - Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
• C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
• C07D 403/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
• C07D 417/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
• C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
• C07D 487/04 - Ortho-condensed systems

Abstract

The present invention relates i.a. to an IBV (infectious bronchitis virus) encoding for a heterologous DMV S (spike) protein or fragment thereof. Further, the present invention relates to an immunogenic composition comprising said IBV encoding for a heterologous DMV S (spike) protein or fragment thereof. Furthermore, the present invention relates to methods for immunizing a subject comprising administering to such subject the immunogenic composition of the present invention. Moreover, the present invention relates to methods of treating or preventing clinical signs caused by IBV in a subject of need, the method comprising administering to the subject a therapeutically effective amount of an immunogenic composition according to the present invention.

IPC Classes  ?

• A61K 39/12 - Viral antigens
• A61P 31/14 - Antivirals for RNA viruses

Abstract

Provided is a new means for mitigating skin pigmentation.　This composition contains the following components (A), (B), (C), and (D). (A) Vitamin C; (B) cysteine or a salt thereof, or a solvate of these; (C) vitamin B6; (D) one or more components selected from thioctic acid and vitamin E.

IPC Classes  ?

• A61K 31/375 - Ascorbic acid, i.e. vitamin CSalts thereof
• A61K 8/44 - Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfurSalts, esters or N-acylated derivatives thereof
• A61K 8/49 - Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
• A61K 31/198 - Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
• A61K 31/355 - Tocopherols, e.g. vitamin E
• A61K 31/385 - Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
• A61K 31/4415 - Pyridoxine, i.e.vitamin B6
• A61P 17/00 - Drugs for dermatological disorders
• A61P 43/00 - Drugs for specific purposes, not provided for in groups
• A61Q 19/00 - Preparations for care of the skin

Abstract

The present invention relates to a process for the manufacture of a HER2 inhibitor and compounds that are useful as intermediates in this process.

IPC Classes  ?

• A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• A61P 35/00 - Antineoplastic agents
• A61P 31/00 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
• C07D 487/04 - Ortho-condensed systems

Abstract

ciscis-5-(hydroxymethyl)morpholine-2-carboxamides that are agonists of somatostatin receptor 4 (SSTR4), and are therefore useful for the treatment of diseases or medical conditions associated with SSTR4. Also provided are pharmaceutical compositions containing the same, and processes for preparing said compounds.

IPC Classes  ?

• A61P 25/00 - Drugs for disorders of the nervous system
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
• C07D 265/30 - 1,4-OxazinesHydrogenated 1,4-oxazines not condensed with other rings
• C07D 413/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
• A61K 31/5375 - 1,4-Oxazines, e.g. morpholine

Goods & Services

(1) Pharmaceutical preparations for the prevention and treatment of diseases and disorders of the alimentary tract and metabolism, namely, renal diseases, liver diseases, pancreas diseases, digestive system disorders, gastrointestinal diseases and disorders, obesity; pharmaceutical preparations for the prevention and treatment of diseases and disorders of the blood and blood forming organs, namely, vascular diseases, hematology, blood disorders; pharmaceutical preparations for the prevention and treatment of cardiovascular diseases and disorders, musculoskeletal diseases and disorders, central nervous system diseases and disorders, peripheral nervous system diseases and disorders; pharmaceutical preparations for the prevention and treatment of genitourinary diseases, urological diseases, infertility, sexually transmitted diseases, inflammatory pelvic diseases; pharmaceutical preparations for the prevention and treatment of respiratory diseases; pharmaceutical preparations for the prevention and treatment of dermatological diseases and disorders, damaged skin and tissues, namely, rashes, sores, psoriasis, eczema; pharmaceutical preparations for the prevention and treatment of inflammation and inflammatory diseases and disorders, namely, anti-inflammatories; pharmaceutical preparations for the prevention and treatment of ophthalmological diseases and disorders; pharmaceutical preparations for the treatment and prevention of hormonal diseases and disorders; pharmaceutical preparations for the treatment and prevention of infectious diseases and disorders and viral infections, namely, antibiotics, anti-infectives, antivirals; pharmaceutical preparations for the prevention and treatment of oncological diseases; pharmaceutical preparations for the prevention and treatment of auto-immune diseases and disorders; pharmaceutical preparations, namely, cell based immune therapeutics for treatment of cancer; pharmaceutical preparations, namely, cell based immune therapeutics for treatment of immunological diseases, namely, autoimmune diseases and disorders; pharmaceutical preparations, namely, cell based immune therapeutics for treatment of infectious diseases, namely viral infections.

Goods & Services

Scientific research in the field of prevention and treatment of cardiovascular diseases; providing medical and scientific research information in the field of cardiovascular diseases.

Goods & Services

Provision of medical research information and scientific information in the field of oncology.

Abstract

The invention concerns an oral pharmaceutical composition consisting essentially of the PDE4B-inhibitor of formula III The invention concerns an oral pharmaceutical composition consisting essentially of the PDE4B-inhibitor of formula III in the dose of 18 mg or 9 mg and optionally of one or more pharmaceutically acceptable carriers or excipients for use in the treatment of a patient suffering from one or more progressive fibrosing interstitial lung diseases (PF-ILD), wherein this oral pharmaceutical composition is to be administered to the patient twice daily. The invention concerns an oral pharmaceutical composition consisting essentially of the PDE4B-inhibitor of formula III in the dose of 18 mg or 9 mg and optionally of one or more pharmaceutically acceptable carriers or excipients for use in the treatment of a patient suffering from one or more progressive fibrosing interstitial lung diseases (PF-ILD), wherein this oral pharmaceutical composition is to be administered to the patient twice daily. The invention further concerns oral pharmaceutical compositions comprising the PDE4B-inhibitor of formula III in the dose of 18 mg or 9 mg and a therapeutically effective dose of a second active ingredient selected from nintedanib or pirfenidone, wherein these oral pharmaceutical compositions are administered to the patient twice daily.

IPC Classes  ?

• A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 9/28 - DrageesCoated pills or tablets
• A61P 11/00 - Drugs for disorders of the respiratory system

Abstract

A cartridge and a nebulizer for nebulizing a fluid as well as a method for fluidically connecting the cartridge to the nebulizer are proposed. The cartridge comprises a closure with a valve, wherein the valve displaces fluid into the nebulizer when opened. Further, the cartridge forms two axially spaced sealings with the nebulizer when connected.

IPC Classes  ?

• A61M 11/02 - Sprayers or atomisers specially adapted for therapeutic purposes operated by air pressure applied to the liquid to be sprayed or atomised
• A61M 15/00 - Inhalators

Abstract

The present invention relates to a certain DPP-4 inhibitor for use in cardio- and/or renoprotective therapy, including in patients at high vascular risk.

IPC Classes  ?

• A61K 31/522 - Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
• A61K 31/155 - Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (HN=C(OH)NH2), isothiourea (HN=C(SH)—NH2)
• A61K 31/4184 - 1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
• A61K 38/28 - Insulins
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
• A61P 9/00 - Drugs for disorders of the cardiovascular system
• A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• A61P 13/12 - Drugs for disorders of the urinary system of the kidneys

Goods & Services

Provision of medical research information and scientific information in the field of oncology

Goods & Services

Downloadable computer software and downloadable mobile applications for assisting patients with symptoms of central nervous system diseases and disorders by providing lessons and techniques to treat and manage negative symptoms; downloadable computer software and downloadable mobile applications to assist patients with mental illness and disorders by providing lessons and techniques to treat and manage negative symptoms. Therapeutic healthcare services for patients with symptoms of diseases and disorders of the central nervous system; therapeutic healthcare services for patients to support mental health.

Abstract

The invention concerns an oral pharmaceutical composition comprising either 18 mg or 9 mg of the PDE4B-inhibitor of formula III The invention concerns an oral pharmaceutical composition comprising either 18 mg or 9 mg of the PDE4B-inhibitor of formula III a therapeutically effective dose of a second active agent selected from the group consisting of nintedanib or pirfenidone and optionally, one or more pharmaceutically acceptable carriers or excipients for the treatment of a patient suffering from a progressive fibrosing interstitial lung disease (PF-ILD), wherein this oral pharmaceutical composition is to be administered to said patient twice daily. The invention concerns an oral pharmaceutical composition comprising either 18 mg or 9 mg of the PDE4B-inhibitor of formula III a therapeutically effective dose of a second active agent selected from the group consisting of nintedanib or pirfenidone and optionally, one or more pharmaceutically acceptable carriers or excipients for the treatment of a patient suffering from a progressive fibrosing interstitial lung disease (PF-ILD), wherein this oral pharmaceutical composition is to be administered to said patient twice daily. The invention further concerns the use of the PDE4B-inhibitor of formula III for preparing an oral pharmaceutical composition comprising either 18 mg or 9 mg of the PDE4B-inhibitor of formula III for use in a method of treating a patient suffering from one or more Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs), wherein said oral pharmaceutical composition is to be orally administered twice daily to said patient in combination with a therapeutically effective amount of a therapeutically effective dose of a second active agent selected from the group consisting of nintdanib and pirfenidone.

IPC Classes  ?

• A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 31/4418 - Non-condensed pyridinesHydrogenated derivatives thereof having a carbocyclic ring directly attached to the heterocyclic ring, e.g. cyproheptadine
• A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
• A61P 11/00 - Drugs for disorders of the respiratory system

Abstract

The present invention encompasses compounds of formula (I) The present invention encompasses compounds of formula (I) The present invention encompasses compounds of formula (I) wherein R1a, R1b, R2a, R2b, Z, R3 to R5, ring A, ring B, p, q, V and W have the meanings given in the claims and specification, their use as inhibitors of KRAS, pharmaceutical compositions and preparations containing such compounds and their use as medicaments/medical uses, especially as agents for treatment and/or prevention of oncological diseases.

IPC Classes  ?

• C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
• A61K 31/52 - Purines, e.g. adenine
• A61K 31/527 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim spiro-condensed
• A61K 31/5386 - 1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
• A61P 35/00 - Antineoplastic agents

Goods & Services

Downloadable computer software and downloadable mobile applications for assisting patients with symptoms of central nervous system diseases and disorders by providing lessons and techniques to treat and manage negative symptoms; downloadable computer software and downloadable mobile applications to assist patients with mental illness and disorders by providing lessons and techniques to treat and manage negative symptoms Therapeutic healthcare services for patients with symptoms of diseases and disorders of the central nervous system; therapeutic healthcare services for patients to support mental health

Goods & Services

(1) Pharmaceutical preparations for the prevention and treatment of diseases and disorders of the alimentary tract and metabolism, namely, renal diseases, liver diseases, pancreas diseases, digestive system disorders, gastrointestinal diseases and disorders, obesity; pharmaceutical preparations for the prevention and treatment of diseases and disorders of the blood and blood forming organs, namely, vascular diseases, hematology, blood disorders; pharmaceutical preparations for the prevention and treatment of cardiovascular diseases and disorders, musculoskeletal diseases and disorders, central nervous system diseases and disorders, peripheral nervous system diseases and disorders; pharmaceutical preparations for the prevention and treatment of genitourinary diseases, urological diseases, infertility, sexually transmitted diseases, inflammatory pelvic diseases; pharmaceutical preparations for the prevention and treatment of respiratory diseases; pharmaceutical preparations for the prevention and treatment of dermatological diseases and disorders, damaged skin and tissues, namely, rashes, sores, psoriasis, eczema; pharmaceutical preparations for the prevention and treatment of inflammation and inflammatory diseases and disorders, namely, anti-inflammatories; pharmaceutical preparations for the prevention and treatment of ophthalmological diseases and disorders; pharmaceutical preparations for the treatment and prevention of hormonal diseases and disorders; pharmaceutical preparations for the treatment and prevention of infectious diseases and disorders and viral infections, namely, antibiotics, anti-infectives, antivirals; pharmaceutical preparations for the prevention and treatment of oncological diseases; pharmaceutical preparations for the prevention and treatment of auto-immune diseases and disorders; pharmaceutical preparations, namely, cell based immune therapeutics for treatment of cancer; pharmaceutical preparations, namely, cell based immune therapeutics for treatment of immunological diseases, namely, autoimmune diseases and disorders; pharmaceutical preparations, namely, cell based immune therapeutics for treatment of infectious diseases, namely viral infections.

Goods & Services

Downloadable computer software and downloadable mobile applications for assisting patients with symptoms of central nervous system diseases and disorders by providing lessons and techniques to treat and manage negative symptoms; downloadable computer software and downloadable mobile applications to assist patients with mental illness and disorders by providing lessons and techniques to treat and manage negative symptoms Therapeutic healthcare services for patients with symptoms of diseases and disorders of the central nervous system; therapeutic healthcare services for patients to support mental health

Goods & Services

Veterinary preparations for pets for the treatment of hypertension; veterinary preparations for pets for the treatment of chronic kidney disease; veterinary preparations for pets for the treatment of diseases and disorders of the alimentary tract and metabolism; veterinary preparations for the treatment of diseases and disorders of the cardiovascular system.

Goods & Services

Pharmaceutical preparations.

Goods & Services

Interactive databases containing information in the field of parasites in pets; computer applications and internet-based applications in the field of parasites in pets; software and software applications for mobile devices in the field of parasites in pets. Providing medical and scientific research information in the field of parasites in pets. Veterinary services provided via mobile application software in the field of parasites in pets.

Goods & Services

Veterinary preparations.

Goods & Services

Veterinary preparations.

Goods & Services

Veterinary preparations.

Goods & Services

Veterinary preparations.

Goods & Services

Pharmaceutical preparations.

Abstract

Shown and described is a holding device (1) for a dispensing device (2), in particular for an autoinjector, for substance dispensing at least one therapeutically and/or diagnostically effective substance. According to the invention, it is provided that the holding device (1) is embodied as a multi-holder for holding two or more dispensing devices (2) on the holding device (1) and, in the state of holding the dispensing devices (2), for substance dispensing via at least one dispensing device (2) held on the holding device (1).

IPC Classes  ?

• A61M 5/31 - Syringes Details
• A61M 5/20 - Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically